Aside from Seagen, small takeouts dominate the first quarter.
Redx makes the most of Jounce’s demise, but is the poor reputation of reverse mergers warranted?
The remarkable thing is that these tie-ups are still occurring, so atrocious is their track record.
December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.
Research-stage buyouts are as expensive as ever, while commercial assets look to be getting dearer, a new analysis finds.
It is hard to see a combination of the two businesses as much beyond a defensive move in troubled times.
Pfizer's Covid cash keeps the M&A scene alive, but few other developers dug deep in a quiet third quarter.